Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/12337
Title: Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer
Authors: Gill, S.
Berry, S.
Biagi, J.
Butts, C.
BUYSE, Marc 
Chen, E.
Jonker, D.
Marginean, C.
Samson, B.
Stewart, J.
Thirlwell, M.
Wong, R.
Maroun, J. A.
Issue Date: 2011
Publisher: MULTIMED INC
Source: CURRENT ONCOLOGY, (18 (Supplement 2)). p. S5-S10
Abstract: In recent years, significant advances have been made in the management of metastatic colorectal cancer. Traditionally, an improvement in overall survival has been considered the "gold standard" the most convincing measure of efficacy. However, overall survival requires larger patient numbers and longer follow-up and may often be confounded by other factors, including subsequent therapies and crossover. Given the number of active therapies for potential investigation, demand for rapid evaluation and early availability anew therapies is growing. Progression-free survival is regarded as an important measure of treatment benefit and, compared with overall survival, can be evaluated earlier, with fewer patients and no confounding by subsequent lines of therapy. The present paper reviews the advantages, limitations, and relevance of progression-free survival as a primary endpoint in randomized trials of metastatic colorectal cancer.
Notes: [Gill, S] BC Canc Agcy, Vancouver, BC V5Z 4E6, Canada. [Gill, S] Univ British Columbia, Div Med Oncol, Vancouver, BC V5Z 1M9, Canada. [Berry, S] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. [Berry, S] Univ Toronto, Toronto, ON, Canada. [Biagi, J] Queens Univ, Dept Oncol, Kingston, ON, Canada. [Butts, C] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada. [Butts, C] Univ Alberta, Edmonton, AB, Canada. [Buyse, M] Int Inst Drug Dev, Louvain, Belgium. [Buyse, M] Hasselt Univ, I BioStat, Diepenbeek, Belgium. [Chen, E] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada. [Jonker, D; Maroun, JA] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada. [Marginean, C] Ottawa Hosp Res Inst, Ottawa, ON, Canada. [Samson, B] LHop Charles Lemoyne, Ctr Integre Canc Monteregie, Greenfield Pk, PQ, Canada. [Stewart, J] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON, Canada. [Thirlwell, M] Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada. [Thirlwell, M] McGill Univ, McGill Univ Hlth Ctr, Montreal, PQ, Canada. [Wong, R] Univ Manitoba, Winnipeg, MB, Canada. [Maroun, JA] Univ Ottawa, Ottawa, ON, Canada. sgill@bccancer.bc.ca
Keywords: Progression-free survival; metastatic colorectal cancer; surrogate endpoints; targeted therapies; randomized clinical trials
Document URI: http://hdl.handle.net/1942/12337
ISSN: 1198-0052
e-ISSN: 1718-7729
ISI #: 000296180000002
Category: A1
Type: Journal Contribution
Validations: ecoom 2012
Appears in Collections:Research publications

Show full item record

WEB OF SCIENCETM
Citations

20
checked on May 14, 2022

Page view(s)

44
checked on May 17, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.